Index Endoscopic Restrictive and Other Devices in Obesity Treatment: Techniques and Outcomes

  • Bruce Schirmer
  • Peter Adams


This chapter describes the major intragastric endoscopic restrictive devices currently in use and in development to aid in weight loss for the obese patient. By far the most commonly used and prolific of these devices is the intragastric balloon, of which three types are now FDA approved in the USA, with others available internationally. Many thousands of patients have had such balloons placed, usually for up to 6 months per balloon. Other devices approved for gastric suturing have been adapted for weight reduction procedures, such as the endoscopic sleeve gastroplasty. Space-occupying products of other types, including stents, expanding ingested beads, and devices which partially obstruct the pylorus are also described.


Intragastric balloon Endoscopic restrictive procedures Endoscopic sleeve gastroplasty Transpyloric shuttle Satisphere 


  1. 1.
    Hogan RB, Johnston JH, Long BW, et al. A double-blind, randomized, sham-controlled trial of the gastric bubble for obesity. Gastrointest Endsc. 1989;35(3):381–5.CrossRefGoogle Scholar
  2. 2.
    Genco A, Bruni T, Doldi SB, et al. BioEnterics intragastric balloon: the Italian experience with 2,515 patients. Obes Surg. 2005;15(8):1161–4.CrossRefPubMedGoogle Scholar
  3. 3.
    Sallet JA, Marchesini JB, Paiva DS, et al. Brazilian multicenter study of the intragastric balloon. Obes Surg. 2004;14(7):991–8.CrossRefPubMedGoogle Scholar
  4. 4.
    Imaz I, Martinez-Cervell C, Garcia-Alvarez EE, et al. Safety and effectiveness of the intragastric balloon for obesity. A meta-analysis. Obes Surg. 2008;18(7):841–6.CrossRefPubMedGoogle Scholar
  5. 5.
    ASGE Bariatric Endoscopy Task force and ASGE technology committee, Abu Dayyeh BK, Kumar N, Edmundowicz SA, et al. ASGE bariatric endoscopy task force systematic review and meta-analysis assessing the ASGE PIVI thresholds for adopting endoscopic bariatric therapies. Gastrointest Endosc. 2015;82(3):425–38.CrossRefGoogle Scholar
  6. 6.
  7. 7.
    Ponce J, Woodman G, Swain J, et al. The REDUCE pivotal trial: a prospective randomized controlled pivotal trial of a dual intragastric balloon for the treatment of obesity. Surg Obes Rel Dis. 2015;11(4):874–81.CrossRefGoogle Scholar
  8. 8.
  9. 9.
    DePeppo F, Caccamo R, Adorisio O, et al. The Obalon swallowable intragastric balloon in pediatric and adolescent morbid obesity. Endosc Int Open. 2017;5:E59–63.CrossRefGoogle Scholar
  10. 10.
    Brooks J, Srivasta ED, Mathus-Vligen EM. One-year adjustable intragastric balloons: results in 73 consecutive patients in the U.K. Obes Surg. 2014;24:813–9.CrossRefPubMedGoogle Scholar
  11. 11.
    Machytka E, Puig Divi V, Saenger F, et al. Adjustable balloons for weight loss: a higher yield of responders compared with non-adjustable balloons. Chicago: ASGE Poster Session, Digestive Disease Week; 2017.Google Scholar
  12. 12.
    Raftopoulos I, Giannakou A. The Elipse balloon, a swallowable gastric balloon for weight loss not requiring sedation, anesthesia, or endoscopy: a pilot study with 12-month outcomes. Surg Obes Rel Dis. 2017;13:1174–82.CrossRefGoogle Scholar
  13. 13.
    Tate CM, Geliebter A. Intragastric balloon treatment for obesity: review of recent studies. Adv Ther 2017;34(8):1859–75.Google Scholar
  14. 14.
    “Liquid filled intragastric balloon systems: Letter to healthcare providers – potential risks.” FDA safety alert. Published August 8, 2017.
  15. 15.
    “Smart pill” reduces weight in overweight and obese subjects. ScienceDaily 2014; Available at: Accessed July 13, 2015.
  16. 16.
    Sharaiha RZ, Kumta NA, DeFillipis DM, et al. A large multicenter experience with endoscopic suturing for management of gastrointestinal defects and stent anchorage in 122 patients: a retrospective review. J Clin Gastroenterol. 2016;50:388–92.PubMedGoogle Scholar
  17. 17.
    Vargas EJ, Bazerbachi F, Rizk M, et al. Transoral outlet reduction with full thickness endoscopic suturing for weight regain after gastric bypass: a large multicenter international experience and meta-analysis. Surg Endosc. 2017 epub ahead of print 2017 June 29
  18. 18.
    Lopez-Nava G, Sharaiha RZ, Vargas EJ, et al Endoscopic sleeve gastroplasty for morbid obesity: a multicenter study of 248 patients with 24 months follow-up. Obes Surg 2017;27(10):2644–55.Google Scholar
  19. 19.
    Sharaiha RZ, Kumta NA, Saumoy M, et al. Endoscopic sleeve gastroplasty significantly reduces body mass index and metabolic complications in obese patients. Clin Gastroenterol Hepatol. 2017;15:504–10.CrossRefPubMedGoogle Scholar
  20. 20.
    Sullivan S, Edmundowicz SA, Thompson CC. Endoscopic bariatric and metabolic therapies: new and emerging technologies. Gastroenterology. 2017;152(7):1791–801.CrossRefPubMedGoogle Scholar
  21. 21.
    Marinos G, Eliades C, Raman Muthusamy V, Greenway F. Weight loss and improved quality of life with a nonsurgical endoscopic treatment for obesity: clinical results from a 3- and 6-month study. Surg Obes Relat Dis. 2014;10(5):929–34.CrossRefPubMedGoogle Scholar
  22. 22.
    Bazerbachi F, Vargas Valls EJ, Abu Dayyeh BK. Recent clinical results of endoscopic bariatric therapies as an obesity intervention. Clin Endosc. 2017;50(1):42–50.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Dayyeh A, BK ESA, Jonnalagada S, et al. ASGE endoscopy bariatric task force; ASGE technology committee. Endosc Baria Ther Gastrointest Endosc. 2015;81(5):1073–86.CrossRefGoogle Scholar
  24. 24.
    Dargent J. Innovative technologies and non-invasive procedures in bariatric surgery, vol. 27. New York: Springer Science; 2013.CrossRefGoogle Scholar
  25. 25.
    Bariatric News; Prevail Implant System; Studies show new bariatric implant is “safe and effective. July 2012.
  26. 26.
    Kumar N. Endoscopic therapy for weight loss: Gastroplasty, duodenal sleeves, intragastric balloons, and aspiration. World J Gastrointest Endosc. 2015;7(9):847–59.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Sauer N, Rösch T, Pezold J, et al. A new endoscopically implantable device (SatiSphere) for treatment of obesity–efficacy, safety, and metabolic effects on glucose, insulin, and GLP-1 levels. Obes Surg 2013 23(11):1727–33.Google Scholar
  28. 28.
    Fiona Sander. Clinical investigation report: pre-market study to investigate the safety and performance of the SatiSphere® Duodenal insert in overweight and obese patients. CRO Medpace: 2017.Google Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of SurgeryUniversity of Virginia Health SystemCharlottesvilleUSA

Personalised recommendations